<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="218223">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00243711</url>
  </required_header>
  <id_info>
    <org_study_id>AG9689-001</org_study_id>
    <nct_id>NCT00243711</nct_id>
  </id_info>
  <brief_title>A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      The efficacy, safety and acceptability of an investigational lubricant eye drop in subjects
      with dry eye will be evaluated in comparison with currently-available lubricant eye drops.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dry Eye Symptoms</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular surface damage, tear stability, tear production</measure>
  </secondary_outcome>
  <enrollment type="Actual">286</enrollment>
  <condition>Dry Eye</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboxymethylcellulose sodium and Glycerin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild, Moderate, or Severe Dry Eye Symptoms and current eye drop use;

          -  Reduced tear stability or tear production

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Curtis, O.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>InSight Eyecare</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Warrensburg</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <lastchanged_date>May 27, 2011</lastchanged_date>
  <firstreceived_date>October 21, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Allergan, Inc</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
